Ligand partner Pelthos launches ZELSUVMI topical gel

Ligand (LGND) Pharmaceuticals announced that its partner Pelthos Therapeutics has commercially launched ZELSUVMI topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5M milestone payment from Pelthos following the commercial launch of ZELSUVMI. Following the completion of the merger between Pelthos Therapeutics and Channel Therapeutics in July 2025, Ligand now owns 56% of Pelthos. Additionally, under the terms of the license agreement with Pelthos, Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and up to an additional $5 million in commercial sales milestones.